The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.26 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.62 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as ANI PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Rare Disease and Brands total net revenues$484.0M
- Rare Disease total net revenues$422.6M
- Generics and Other total net revenues$399.4M
- Unapproved Products$24.1M
Leadership changes
From ANI PHARMACEUTICALS INC's own filings, the day they're filed.
- Matt Leonard · Chief Pharmacy Strategy Officer of Capsule · appointmenteff. 2023-08-21
- Thomas J. Haughey · Chairman · departure
Latest filings
- 8-K · Company announcement2026-05-21
- 8-K · Company announcement2026-05-13
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-05-08
- DEF 14A · Annual proxy (pay & governance)2026-04-09
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about ANI PHARMACEUTICALS INC, every answer cited🔒
- The Intelligence Brief — added when ANI PHARMACEUTICALS INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.